- Industry Size (2025)
- USD 2.47 Bn
- Forecast (2035)
- USD 4.21 Bn
- CAGR (2025 to 2035)
- 5.5%
Breast Biopsy Devices Market Size and Share Forecast Outlook 2025 to 2035
The global Breast Biopsy Devices Market is projected to be valued at USD 2.47 billion in 2025 and is expected to reach USD 4.21 billion by 2035, registering a CAGR of 5.5% during the forecast period. This growth is primarily driven by the increasing prevalence of breast cancer, which necessitates early and accurate diagnostic procedures.
Advancements in minimally invasive biopsy techniques, such as vacuum-assisted and image-guided systems, are enhancing diagnostic accuracy while improving patient comfort and reducing recovery times. Government initiatives promoting breast cancer awareness and screening programs further contribute to market expansion by encouraging early detection and diagnosis.
The rising demand for outpatient and ambulatory surgical centres, coupled with favourable reimbursement policies, is also facilitating the adoption of advanced biopsy devices. Collectively, these factors underscore the market's positive trajectory and the growing emphasis on early and precise breast cancer diagnosis.
Prominent players in the breast biopsy devices market include Hologic, Inc., Devicor Medical Products, Inc. (Mammotome), and Becton, Dickinson and Company (BD). Hologic maintains a significant market share, attributed to its comprehensive portfolio of vacuum-assisted biopsy systems and integrated imaging solutions.
In 2024 - Mammotome announced Mammotome RevolveTM biopsy system, an advanced tissue management system that automatically collects and organizes specimens in touch-free chambers, simplifying tissue verification. “The launch of the newly refined Mammotome RevolveTM system2 marks an exciting milestone for Mammotome,” said Suzanne Smith, Vice President of America Sales, Global Service and Commercial Marketing.
“These enhancements will empower clinicians to perform biopsy procedures with greater simplicity and efficiency. This advancement underscores our unwavering commitment to innovation and excellence in patient care.”
| Attributes | Key Insights |
|---|---|
| Historical Size, 2024 | USD 2.34 billion |
| Estimated Size, 2025 | USD 2.47 billion |
| Projected Size, 2035 | USD 4.21 billion |
| Value-based CAGR (2025 to 2035) | 5.5% |
North America leads the breast biopsy devices market, driven by advanced healthcare infrastructure, high adoption of cutting-edge biopsy technologies, and strong presence of key market players. The region's dominance is further supported by government initiatives promoting breast cancer awareness and screening programs, leading to early detection and diagnosis.
The integration of AI in imaging and biopsy procedures is streamlining workflows and improving diagnostic outcomes. Additionally, favourable reimbursement policies and the rising demand for outpatient and ambulatory surgical centres are facilitating the adoption of advanced biopsy devices.
Europe holds a significant share in the breast biopsy devices market, attributed to the rising prevalence of breast cancer, particularly in countries like Italy, Germany, and the Netherlands. The region's growth is bolstered by high adoption of novel technologies, development in healthcare infrastructure, and government initiatives to create awareness about breast cancer diagnosis programs.
The European market is also witnessing increased investment in research and development of minimally invasive procedures, enhancing diagnostic accuracy and patient comfort. Furthermore, favourable reimbursement policies and the presence of leading manufacturers contribute to the market's expansion.
Semi Annual Market Update
The below table presents the expected CAGR for the global breast biopsy devices market over several semi-annual periods spanning from 2025 to 2035. In the first half (H1) of the decade from 2024 to 2034, the business is predicted to surge at a CAGR of 6.2%, followed by a slightly lower growth rate of 5.9% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 (2024 to 2034) | 6.2% |
| H2 (2024 to 2034) | 5.9% |
| H1 (2025 to 2035) | 5.5% |
| H2 (2025 to 2035) | 5.0% |
Moving into the subsequent period, from H1 2025 to H2 2035, the CAGR is projected to decrease slightly to 5.5% in the first half and decrease moderately at 5.0% in the second half. In the first half (H1) the market witnessed a decrease of 70.00 BPS while in the second half (H2), the market witnessed an increase of 90.00 BPS.
Analyzing Breast Biopsy Devices Market by Top Investment Segments
Suspicious Solid Mass Leads the Market Due to Rising Detection Rates and Clinical Emphasis on Benign Tumor Differentiation
The suspicious solid mass (fibroadenoma) segment is expected to contribute approximately 29.7% of the global revenue share in the breast biopsy devices market in 2025. This segment has emerged as the leading indication due to the widespread occurrence of fibroadenomas, particularly in younger and middle-aged women. The increased availability and usage of imaging techniques, including mammography and ultrasound, have led to the early identification of solid breast masses that require biopsy for conclusive diagnosis.
Clinical focus has been increasingly placed on distinguishing benign tumors such as fibroadenomas from malignant lesions to avoid overtreatment and reduce diagnostic uncertainty. The growth of this segment has been further supported by the integration of minimally invasive techniques such as core needle and vacuum-assisted biopsies-into standard diagnostic protocols.
Hospitals Lead the Market Due to Advanced Diagnostic Infrastructure and High Procedure Volumes
Hospitals are projected to account for nearly 36.8% of the global revenue share in the breast biopsy devices market in 2025, making them the dominant end-user segment. This leading position is attributed to hospitals’ access to advanced imaging modalities, specialized diagnostic teams, and integrated care settings, which are essential for the safe and accurate execution of breast biopsy procedures.
Hospitals are typically equipped with MRI-guided and stereotactic biopsy systems, allowing for comprehensive diagnostic workflows in a single location. A significant volume of breast biopsies especially those involving complex cases or high-risk patients is conducted within hospitals due to their ability to coordinate across radiology, oncology, and pathology departments.
Furthermore, structured reimbursement frameworks and insurance coverage in most countries make hospitals the primary point of care for such procedures. The continued expansion of hospital-based breast care units and growing investments in precision diagnostic tools have also contributed to the consolidation of hospitals as the preferred setting for biopsy. These factors collectively reinforce hospitals’ central role in breast cancer diagnostics and drive their market dominance.
Key Industry Highlights
The Expansion of Screening Programs and Awareness Campaigns Is Driving the Growth for Breast biopsy devices market.
Government and non-governmental associations across the world have focused on creating breast cancer awareness and early detection through comprehensive initiatives. These programs will help the public understand the importance of regular checkups, why they are risky, and possibly help the patient survive earlier.
For example, activities like Breast Cancer Awareness Month spearheaded by any organization like the American Cancer Society (ACS) and World Health Organization (WHO) have been crucial in fostering awareness across the globe.
Mass screening programs, especially mammography, form the core of these efforts. With such programs being initiated, thousands of women become a part of routine screening processes, which mostly reveal suspicious lesions or abnormalities in the breast tissue.
The discovery of these anomalies calls for further diagnostic evaluation, and the gold standard for the final diagnosis is breast biopsy. This direct correlation of increased screening efforts with the need for biopsy procedures has driven the advancement of breast biopsy devices.
Advancements in image-guided biopsy techniques have now made follow-up evaluations more efficient as well as highly accurate, well in line with the objectives behind such awareness measures that would ultimately allow for time- and evidence-based diagnosis. This increases the cumulative pool of the patient population getting biopsy procedures thus becoming an overarching factor in the acceleration of the demand for breast biopsy devices.
Advancements in Vacuum-Assisted Biopsy (VAB) Systems Are a Key Driver of Growth in The Market for breast biopsy devices
These systems have revolutionized the way breast tissue samples are collected, offering significant advantages over traditional biopsy techniques. Unlike conventional methods, VAB systems use a vacuum mechanism to extract tissue samples, enabling the collection of larger and more intact specimens.
This ability to obtain high-quality samples improves diagnostic precision, particularly in detecting subtle or early-stage abnormalities, which are crucial for effective breast cancer diagnosis and treatment planning.
The minimally invasive nature of VAB systems has pushed forward their application further. Such instruments can accurately reach small or located lesions which other techniques might have difficulty reaching.
The technique can be guided through advanced imaging techniques such as ultrasound, mammography, or MRI, to provide accuracy in collecting samples and limiting damage to other tissues. This makes VAB a patient-friendly option, reducing recovery time, procedure-related discomfort, and the need for repeat biopsies.
In addition, improvements in VAB systems, such as automation and ergonomic designs, have streamlined the process for clinicians to be faster and more efficient. These advancements are in line with the increased need for cost-effective, accurate, and patient-centered diagnostic solutions in modern healthcare settings.
Therefore, the constant improvement and adoption of VAB systems have become a significant driver of the expansion of the market for breast biopsy devices.
The Increasing Preference for Outpatient Settings Like Ambulatory Surgical Centers (ASCs) For Performing Biopsy Procedures Presents a Significant Opportunity
Ambulatory surgical centers have become the preference for patients and healthcare providers as they are less expensive, require shorter waiting periods, and the whole process runs much more efficiently than in hospitals. The growth of outpatient care has been further encouraged by a rising demand for minimally invasive procedures that take much less time and can be accomplished with minimal recovery time, so breast biopsies are most suitable for such ASCs.
This has opened up an area for manufacturers to develop compact, portable, and easy-to-use biopsy devices suitable for the ASCs requirements. The devices have to be manufactured keeping in mind the need for high precision and efficiency while being user-friendly to clinicians who function in a high-pace environment.
In addition, the cost-sensitive nature of the ASC will require diagnostic tools to be affordable yet with advanced technology, an area for innovative biopsy technologies.
In addition, the increasing number of ASCs worldwide, especially in developed and emerging markets, increases the potential customer base for breast biopsy device manufacturers. Devices designed for ASCs not only make procedures more efficient but also increase patient satisfaction due to faster procedures and quicker recovery times. This trend represents untapped growth potential in this market segment.
The Dependence of Breast Biopsy Devices on Advanced Imaging Modalities as Significant Growth Barrier for Market for breast biopsy devices Growth
Advanced imaging modalities such as MRI, mammography, and ultrasound pose a significant restraint on the market for breast biopsy devices, mainly because of resource-limited settings. These imaging systems are an essential part of many biopsy procedures that are performed with precision and effectiveness, because they allow accurate localization and targeting of suspicious lesions.
However, the high cost and need for specialized infrastructure make these unavailable, especially in smaller healthcare facilities and rural areas.
In developing areas or low-income countries, accessibility to advanced imaging technology is confined because of various economic constraints along with low-budget healthcare and inadequacy of infrastructure. Smaller clinics or outpatient centers also refrain from the investment of advanced imaging equipment in the developed regions also, thereby declining their ability for performing advanced biopsies through them.
These restrictions limit the usage of devices that are primarily based on the aforementioned modalities and act as a constraint toward the growth in the market.
In addition, the imaging-guided biopsy systems are operated by trained personnel who have knowledge in both imaging and biopsy techniques. The lack of such trained professionals in many areas aggravates the challenge, leaving some populations underserved.
For manufacturers, this reliance on imaging systems adds complexity, as devices must be designed to integrate seamlessly with a range of imaging technologies, further increasing costs. In summery, the availability of advanced imaging technologies can significantly limit access and widespread acceptance of breast biopsy instruments, limiting growth in low resource regions.
Market Concentration
Tier 1 companies comprise market leaders with a significant market share of 58.9% in global market. These companies engage in strategic partnerships and acquisitions to expand their product portfolios and access cutting-edge technologies. Additionally, they emphasize extensive clinical trials to validate the efficacy and safety of their products. Prominent companies in tier 1 include F. Hoffmann-La Roche Ltd., GE Healthcare, Cook Medical Inc., Becton Dickinson and Company.
Tier 2 companies include mid-size players having presence in specific regions and highly influencing the local market and holds around 21.9% market share. They typically pursue partnerships with multispecialty hospitals and research organizations to leverage emerging technologies and expedite product development.
These companies often emphasize agility and adaptability, allowing them to quickly bring new products to market, additionally targeting specific types medical needs. Additionally, they focus on cost-effective production methods to offer competitive pricing. Prominent companies in tier 2 include Hologic, Inc., Siemens Healthier, ARGON MEDICAL, C.R. Bard, Inc. and Devicor Medical Products, Inc.
Finally, Tier 3 companies, such as Leica Biosystems, Medax Srl Unipersonale, Planmed Oy, and Scion Medical Technologies, LLC. They specialize in specific products and cater to niche markets, adding diversity to the industry.
Overall, while Tier 1 companies are the primary drivers of the market, Tier 2 and 3 companies also make significant contributions, ensuring the breast biopsy devices sales remains dynamic and competitive.
Country-wise Insights
The section below covers the industry analysis for the market for breast biopsy devices for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and Middle Ease & Africa, is provided. The United States is anticipated to remain at the forefront in North America, with higher market share through 2035. In South Asia & Pacific, India is projected to witness a CAGR of 5.5% by 2035.
| Countries | Value CAGR (2025 to 2035) |
|---|---|
| United States | 2.9% |
| Germany | 3.9% |
| France | 3.5% |
| Spain | 4.1% |
| China | 5.1% |
| India | 5.5% |
| Australia & New Zealand | 4.8% |
| Japan | 5.0% |
The High Prevalence of Breast Cancer in The United States Is a Significant Driver for The Market for breast biopsy devices
United States. market for breast biopsy devices is poised to exhibit a CAGR of 2.9% between 2025 and 2035. Currently, it holds the highest share in the North American market.
According to the American Cancer Society (ACS), breast cancer is the most frequently diagnosed cancer among women in the country, with over 300,000 new cases of invasive and non-invasive breast cancer reported annually. This alarming incidence rate has heightened the need for early detection and accurate diagnosis, making advanced diagnostic tools, including breast biopsy devices, essential in healthcare.
Early diagnosis is very important for the effective treatment, and breast biopsy devices play a crucial role in confirming malignancies and guiding therapeutic decisions. This increasing prevalence has also led the government and nongovernmental initiatives to encourage widespread breast cancer screening, often finding suspicious lesions that require biopsy. This steady demand for accurate and reliable diagnostic solutions continues to propel the adoption and development of new and innovative breast biopsy technologies in the USA market.
High Patient Awareness About Breast Cancer and The Importance of Early Detection Is a Significant Driver for The Market for breast biopsy devices in Germany
Germany’s market for breast biopsy devices is poised to exhibit a CAGR of 3.9% between 2025 and 2035. Currently, it holds the highest share in the Western Europe market, and the trend is expected to continue during the forecast period.
The initiatives and healthcare campaigns carried out in Germany have equipped the public with information on breast cancer risks, signs, and early diagnosis benefits. National Mammography Screening Program emphasizes the need for women aged 50-69 years to be screened regularly, allowing for early detection of abnormal lesions in the breast.
This awareness helps to generate proactive healthcare behavior in that among other things, a larger segment of the female population has accepted regular check-ups and these tests. The additional tests are usually followed by biopsy procedures when evidence of abnormality is found.
The seemingly growing demand for such modern and accurate breast biopsy devices can be linked towards the rising awareness on breast cancer found among the various segments of the German population. Along with this is a well-educated and equally health-conscious German populace that promotes an immense call for timely medical intervention, maintaining a steady demand for diagnostic solutions. This focus on awareness and a preventive approach to healthcare also supports powerfully the growth of the market for breast biopsy devices in the country.
Japan's rapidly aging population significantly impacts the market for breast biopsy devices.
Japan market for breast biopsy devices is poised to exhibit a CAGR of 5.0% between 2025 and 2035. Currently, it holds the highest share in the East Asia market, and the trend is expected to continue during the forecast period.
Japan's rapidly aging population significantly impacts the market for breast biopsy devices. As of 2022, over 29% of Japan's population was aged 65 and above, reflecting a substantial increase over the past decade. This demographic shift correlates with a rise in breast cancer cases, particularly among older women. In 2020, approximately 92,150 new breast cancer cases were diagnosed among Japanese women, a significant increase from over 44,000 cases in 2003.
Elderly populations also suffer from hence, putting them at an increased risk of having comorbidities and hence making early diagnosis and the delivery of treatment all the more urgent. Biopsy devices, more so even minimally invasive ones, are now increasingly being embraced in giving appropriate diagnoses with low discomfort to the patient. The health care system in Japan, powered by universal coverage, endorses the systems toward the older generation accessing those tools. The government health initiatives also boost regular screening to assist in early detection of breast lesions that require biopsy.
Competitive Landscape
The market players are using strategies to stay competitive, such as product differentiation through innovative formulations, strategic partnerships with healthcare providers for distribution. Another key strategic focus of these companies is to actively look for strategic partners to bolster their product portfolios and expand their global market presence.
Recent Industry Developments in Market for breast biopsy devices
- In November 2024, GE HealthCare unveiled Pristina Via, a mammography system aimed at enhancing the screening experience for technologists and patients. Pristina Via gives mammography technologists a suite of tools that balance the demands of diagnostic accuracy and fast-moving workflows to expedite more patient-centered breast care.
- In January 2019, IZI Medical Products, LLC and portfolio company of Shore Capital Partners, LLC announced it has acquired select soft tissue biopsy and breast localization needle assets from Cook Medical (Cook). The acquired portfolio of products are commercially marketed under the highly regarded Quick-Core Biopsy Needle, MReye Breast Localization Coil, and the Kopans and X-Reidy Lesion Localization Needles.
Breast Biopsy Devices Industry Outlook, By Key Market Players
- F. Hoffmann-La Roche Ltd.
- GE Healthcare
- Cook Medical Inc.
- Becton Dickinson and Company
- Hologic, Inc.
- Siemens Healthier
- ARGON MEDICAL
- C.R. Bard, Inc.
- Devicor Medical Products, Inc.
- Leica Biosystems
- Medax Srl Unipersonale
- Planmed Oy
- Scion Medical Technologies, LLC
Breast Biopsy Devices Industry Analysis, By Key Segments
By product:
In terms of product, the industry is divided into- biopsy needle, MRI-guide biopsy systems, ultrasound guided breast biopsy systems, vacuum-assisted device (VAD), guide wire (localization wire) and breast biopsy marker.
By Indication:
In terms of indication, the industry is segregated into- complex cyst, solid mass, suspicious solid mass (fibroadenoma) and suspicious micro-calcifications.
By End User:
In terms of end user, the industry is segregated into- hospitals, specialty clinics, ambulatory surgical centers and cancer research institutes.
By Region:
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia and Middle East and Africa (MEA) have been covered in the report.
Frequently Asked Questions
What is the future of global breast biopsy devices market?
The global breast biopsy devices market is projected to witness CAGR of 5.5% between 2025 and 2035.
What was the worth of the global breast biopsy devices market in 2024?
The global breast biopsy devices industry stood at USD 2.34 billion in 2024.
What will the worth of global breast biopsy devices market by 2035 end?
The global breast biopsy devices market is anticipated to reach USD 4.21 billion by 2035 end.
Which country to showcase the highest CAGR during forecast period?
India is set to record the highest CAGR of 6.4% in the assessment period.
Who are the key manufacturer of breast biopsy devices?
The key players operating in the global breast biopsy devices market include F. Hoffmann-La Roche Ltd., GE Healthcare, Cook Medical Inc., Becton Dickinson and Company, Hologic, Inc., Siemens Healthier, ARGON MEDICAL, C.R. Bard, Inc., Devicor Medical Products, Inc., Leica Biosystems, Medax Srl Unipersonale, Planmed Oy, and Scion Medical Technologies, LLC.
Preview the report firsthand - request a free sample
Get SampleGet the brochure for pricing and purchase details.
Get PDFTable of Content
- Executive Summary
- Industry Introduction, including Taxonomy and Market Definition
- Market Trends and Success Factors, including Macro-Economic Factors, Market Dynamics, and Recent Industry Developments
- Global Market Demand (Value in USD) and Volume (Units) Analysis 2020 to 2024 and Forecast 2025 to 2035, including Historical Analysis and Future Projections
- Global Market - Pricing Analysis
- Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035
- By Product
- By Indication
- By End User
- By Region
- Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Product
- Biopsy Needle
- MRI-Guide Biopsy Systems
- Ultrasound Guided Breast Biopsy Systems
- Vacuum-Assisted Device (VAD)
- Guide Wire (Localization Wire)
- Breast Biopsy Marker
- Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Indication
- Complex cyst
- Solid mass
- Suspicious solid mass (fibroadenoma)
- Suspicious micro-calcifications
- Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By End User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Cancer Research Institutes
- Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Region
- North America
- Latin America
- Western Europe
- Eastern Europe
- South Asia & Pacific
- East Asia
- Middle East & Africa
- North America Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
- Latin America Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
- Western Europe Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
- Eastern Europe Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
- South Asia & Pacific Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
- East Asia Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
- Middle East and Africa Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
- Sales Forecast 2025 to 2035 By Product, By Indication and by End User for 30 Countries
- Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
- Company Profile
- F. Hoffmann-La Roche Ltd.
- GE Healthcare
- Cook Medical Inc.
- Becton Dickinson and Company
- Hologic, Inc.
- Siemens Healthier
- ARGON MEDICAL
- C.R. Bard, Inc.
- Devicor Medical Products, Inc.
- Leica Biosystems
- Medax Srl Unipersonale
- Planmed Oy
- Scion Medical Technologies, LLC
